Journal of oral & facial pain and headache · 2025
Estimating risk of reported versus theoretical drug-drug interactions in headaches medicine: an exhaustive comparison between DrugBank and FAERS database for abortive and preventive combinations.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaytser Victor, Hakkinen Ian, Dave Jay, Zhang Pengfei
Аннотация
BACKGROUND: Polypharmacy is common in headache medicine. This project uses DrugBank and Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS) to determine the likelihood of a theoretical and empirically reported interaction between a given number of headache abortive and preventive medications.
METHODS: All headache medications referenced in "The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice" and Szperka's "Migraine care in the era of COVID-19: clinical pearls and plea to insurers" were included. All possible combinations of up to three abortives and preventatives were screened for drug-drug interactions through searches in DrugBank and FAERS. If at least one drug-drug interaction was listed, then it was included in our analysis. The percentage of combinations containing an interaction was then compared across the two databases.
RESULTS: Of the 38 abortives and 23 preventives included, once more than 3 drugs are used in any combination, a drug-drug interaction was >99% likely, per DrugBank. However, per FAERS, the reported interaction was 39% to 60% likely once 3 or 4 drugs are used in any combination. In FAERS, the likelihood of interaction rised most dramatically once 3 or more drugs are used.
CONCLUSIONS: Theoretical interactions, based on DrugBank, maybe overstated when compared to actual observed interactions in FAERS. Future direction is needed delving into the types of interactions recorded in each database.
METHODS: All headache medications referenced in "The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice" and Szperka's "Migraine care in the era of COVID-19: clinical pearls and plea to insurers" were included. All possible combinations of up to three abortives and preventatives were screened for drug-drug interactions through searches in DrugBank and FAERS. If at least one drug-drug interaction was listed, then it was included in our analysis. The percentage of combinations containing an interaction was then compared across the two databases.
RESULTS: Of the 38 abortives and 23 preventives included, once more than 3 drugs are used in any combination, a drug-drug interaction was >99% likely, per DrugBank. However, per FAERS, the reported interaction was 39% to 60% likely once 3 or 4 drugs are used in any combination. In FAERS, the likelihood of interaction rised most dramatically once 3 or more drugs are used.
CONCLUSIONS: Theoretical interactions, based on DrugBank, maybe overstated when compared to actual observed interactions in FAERS. Future direction is needed delving into the types of interactions recorded in each database.